

# Brompton Global Healthcare Income & Growth ETF

## Summary of Investment Portfolio

as at December 31, 2023

**Total Net Asset Value**                      \$                      **51,349,236**

Portfolio Composition	% of Net Asset Value
<b>Europe</b>	
<b>Denmark</b>	
Pharmaceuticals	4.7%
<b>Great Britain</b>	
Pharmaceuticals	8.5%
<b>Total Europe</b>	<b>13.2%</b>
<b>North America</b>	
<b>United States</b>	
Pharmaceuticals	21.7%
Healthcare Equipment	19.6%
Healthcare Distributors	12.4%
Biotechnology	11.4%
Healthcare Supplies	4.8%
Managed Healthcare	4.7%
Healthcare Facilities	4.5%
Life Sciences Tools & Services	2.4%
Healthcare Services	2.4%
<b>Total North America</b>	<b>83.9%</b>
<b>Total Investments</b>	<b>97.1%</b>
Cash	0.8%
Other net assets (liabilities)	2.1%
<b>Total Net Asset Value</b>	<b>100.0%</b>

Holdings	% of Net Asset Value
Dexcom Inc.	5.3%
Boston Scientific Corp.	5.2%
Intuitive Surgical Inc.	5.0%
Abbvie Inc.	5.0%
Eli Lilly and Co.	4.9%
AstraZeneca PLC	4.8%
West Pharmaceutical Servic	4.8%
Novo Nordisk A/S	4.7%
UnitedHealth Group Inc.	4.7%
Cencora Inc.	4.6%
Merck & Co Inc.	4.6%
Zoetis Inc.	4.5%
HCA Healthcare Inc.	4.5%
Johnson & Johnson	4.3%
Mckesson Corp.	4.2%
Stryker Corp.	4.1%
Gilead Sciences Inc.	3.8%
GSK PLC	3.7%
Cardinal Health Inc.	3.6%
Pfizer Inc.	3.4%
Vertex Pharmaceuticals Inc.	2.6%
Agilent Technologies Inc.	2.4%
Cigna Group	2.4%
Cash	0.8%
<b>Total</b>	<b>97.9%</b>

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available on the Fund's website at [www.bromptongroup.com](http://www.bromptongroup.com) within 60 days of each quarter end.